Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070616 | 0.89 | ELANE (0.44) | ELANE | |
| SCHEMBL20140623 | 0.82 | ELANE (0.45) | ELANEKDM4DL3MBTL1MAT2AMETAP2 | |
| SCHEMBL7907355 | 0.80 | ELANE (0.43) | ELANEL3MBTL1HTR2BHTR3AHTR4 | |
| SCHEMBL9925305 | 0.80 | ELANE (0.50) | ELANEKDM4DL3MBTL1 | |
| SCHEMBL10063592 | 0.79 | ELANE (0.47) | ELANEKDM4DL3MBTL1 | |
| SCHEMBL31469634 | 0.78 | GUCY1A1 (0.34) | MAT2A | |
| SCHEMBL17435113 | 0.78 | GUCY1A1 (0.34) | MAT2A | |
| SCHEMBL20140783 | 0.76 | L3MBTL1 (0.63) | ELANEL3MBTL1KDM4E | |
| SCHEMBL20140434 | 0.76 | L3MBTL1 (0.46) | ELANEL3MBTL1KDM4E | |
| SCHEMBL2882941 | 0.76 | ELANE (0.44) | ELANEPDE5AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | ELANE 1617/4885PDE5A 7/4885KDM4D 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.